2024
Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL).
Posadas E, Gay H, Rodgers J, Morgan T, Xiao Y, Yu J, Michalski J, Bouchard M, Desai N, Funk R, Boike T, Jurgens D, Wong A, Shen X, Miyawaki L, Bland C, Hairston J, Sandler H, Pugh S, Feng F. Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL). Journal Of Clinical Oncology 2024, 42: 131-131. DOI: 10.1200/jco.2024.42.4_suppl.131.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression free survivalSalvage radiotherapyHigh-risk featuresBiochemical relapseHigh-risk patientsRadical prostatectomyLHRH analogsDecreased lymphocytesAndrogen receptorMonths of androgen deprivation therapyGrade 3 adverse eventsProgression free survival benefitStandard androgen deprivation therapyMedian follow-up timeGrade 4 AEsPara-aortic radiotherapyProstate cancer patientsEnzalutamide armGleason 9Salvage radiationDeprivation therapyNodal involvementFree survivalRT boost
2022
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
Runcie K, Dallos M, Khan S, Gray J, Marco P, Ping L, LaTourette D, Anderson C, Spina C, Yu J, Deutsch I, Sheeri S, Gutierrez A, Stein M. A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Journal Of Clinical Oncology 2022, 40: tps5115-tps5115. DOI: 10.1200/jco.2022.40.16_suppl.tps5115.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate-specific antigenTumor-associated antigensBiochemical recurrenceProstate cancerRadiation therapyTumor microenvironmentRadical prostatectomyStudy treatmentPromote anti-tumor immune responsesAntigen-specific T cell responsesBiochemical recurrence of prostate cancerBiochemically recurrent prostate cancerCastration sensitive prostate cancerPSA responseTime to PSA progressionDose of study treatmentAnti-tumor immune responseStandard first-line treatmentEvidence of metastatic diseaseMyeloid-derived suppressor cellsImmunosuppressive regulatory T cellsPeptide antigensLive-attenuated Listeria monocytogenesRecurrent prostate cancer
2020
National trends in the management of patients with positive surgical margins at radical prostatectomy
Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPositive surgical marginsUse of ADTPost-prostatectomy radiation therapyRadiation therapySurgical marginsRadical prostatectomyInitial courseNode-negative prostate cancerPost-operative radiation therapyMultivariable logistic regression modelNational Cancer DatabaseAdverse pathologic featuresManagement of patientsPost-operative managementLogistic regression modelsDeprivation therapySurgical cancersPrimary endpointRT useSecondary endpointsPathologic characteristicsPathologic featuresUninsured statusCancer DatabaseRTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
Posadas E, Gay H, Pugh S, Morgan T, Yu J, Lechpammer S, Feng F. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery. Journal Of Clinical Oncology 2020, 38: tps5601-tps5601. DOI: 10.1200/jco.2020.38.15_suppl.tps5601.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalHigh-risk featuresSalvage radiotherapyBiochemical recurrenceRadical prostatectomyProstate cancerSystemic therapyAndrogen receptorYears of androgen deprivation therapyOccurrence of biochemical failureStandard androgen deprivation therapyRandomized phase II studyIndividualization of radiotherapyNon-steroidal anti-androgenPersistently elevated PSADisease control rateRecurrent prostate cancerSeminal vesicle invasionPara-aortic nodesSuspicious lymph nodesPatient-reported toxicityRisk of progressionOne-sided alphaElevated PSA
2019
Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer
Wang C, Raldow A, Nickols N, Nguyen P, Spratt D, Dess R, Yu J, King C, Chu F, Chamie K, Litwin M, Saigal C, Reiter R, Liu S, Rettig M, Chang A, Steinberg M, Kupelian P, Kishan A. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology 2019, 4: 327-330. PMID: 31411981, DOI: 10.1016/j.euo.2019.01.006.Peer-Reviewed Original ResearchConceptsConcomitant androgen deprivation therapyAndrogen deprivation therapyExternal beam radiotherapyDefinitive external beam radiotherapyHigh-grade prostate cancerGleason grade groupProstate cancerBeam radiotherapyDeprivation therapyGG 4NHW menDuration of androgen deprivation therapyAA menPopulation-based retrospective studyProstate cancer patientsMultiple randomized trialsNon-HispanicInverse probability treatmentSurvival benefitNon-Hispanic white menRetrospective studyRandomized trialsGrade groupRadiotherapyProbability treatment
2018
National trends in the management of patients with positive surgical margins at the time of radical prostatectomy.
Ghabili K, Nguyen K, Hsiang W, Syed J, Suarez-Sarmiento A, Shuch B, Park H, Yu J, Leapman M. National trends in the management of patients with positive surgical margins at the time of radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 111-111. DOI: 10.1200/jco.2018.36.6_suppl.111.Peer-Reviewed Original ResearchAdjuvant radiation therapyAndrogen deprivation therapyPositive surgical marginsNational Cancer DatabaseAdjuvant therapyRadical prostatectomyRadiation therapyProstate cancerPathologic featuresSurgical marginsAddition of ADTAdjuvant androgen deprivation therapyStudy periodPre-treatment PSAPrimary definitive treatmentMajority of patientsManagement of patientsGleason grade groupCourse of managementOptimal management approachNon-academic facilitiesLogistic regression modelsBinary logistic regression modelAnalysis menDeprivation therapyAndrogen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
Yang D, Krasnova A, Nead K, Choueiri T, Hu J, Hoffman K, Yu J, Spratt D, Feng F, Trinh Q, Nguyen P. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Annals Of Oncology 2018, 29: 386-391. PMID: 29267861, DOI: 10.1093/annonc/mdx744.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyDuration of androgen deprivation therapyProstate cancerIncreased riskRheumatoid arthritisDeprivation therapyAutoimmune conditionsAdverse effects of ADTStage I-III prostate cancerEffects of androgen deprivation therapyCompeting risks Cox regressionPharmacological androgen deprivation therapyRA diagnosisLocalized prostate cancerKaplan-Meier ratesRisks Cox regressionInverse probability of treatment weightingProbability of treatment weightingHistory of RACohort of elderly menDiagnosis of RARisk of rheumatoid arthritisUntreated hypogonadismImmunosuppressive propertiesAutoimmune diseases
2016
Impact of Concurrent Androgen-Deprivation Therapy and Radiation Therapy Versus Radiation Therapy Alone on Overall Survival for Men With Unfavorable Intermediate-Risk Prostate Cancer
Johnson S, Lester-Coll N, Stahl J, Nath S, Yu J. Impact of Concurrent Androgen-Deprivation Therapy and Radiation Therapy Versus Radiation Therapy Alone on Overall Survival for Men With Unfavorable Intermediate-Risk Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e240. DOI: 10.1016/j.ijrobp.2016.06.1227.Peer-Reviewed Original Research
2012
The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.
Quon J, Yu J, Soulos P, Gross C. The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. Journal Of Clinical Oncology 2012, 30: e15150-e15150. DOI: 10.1200/jco.2012.30.15_suppl.e15150.Peer-Reviewed Original ResearchHigh-risk groupShort life expectancyRisk groupsProstate cancerLife expectancyNational Comprehensive Cancer Network guidelinesAndrogen deprivation therapy useConcurrent androgen deprivation therapyEnd Results-Medicare databaseAndrogen deprivation therapyLow-risk cancersExternal beam radiationLow-risk groupLonger life expectancyDeprivation therapyNCCN guidelinesOlder patientsClinical factorsTherapy useGuideline recommendationsTumor characteristicsNetwork guidelinesCancer characteristicsRadiation therapyMedicare population